We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $224.49 · 10 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
State grant could help Albemarle attract a neighbor for AstraZeneca - Cville Right Now
State grant could help Albemarle attract a neighbor for AstraZeneca Cville Right Now
Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $222.02 - 富途牛牛
Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $222.02 富途牛牛
Key facts: CSPC nets $1.2B from AstraZeneca; Ennituo cleared in China - TradingView
Key facts: CSPC nets $1.2B from AstraZeneca; Ennituo cleared in China TradingView
AstraZeneca shares subgroup data behind amyloidosis aspirations - FirstWord Pharma
AstraZeneca shares subgroup data behind amyloidosis aspirations FirstWord Pharma
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial - Yahoo
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial Yahoo
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 27. | After market close (AMC) | $1.27 | — | — | $15.42B | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 02. 13. | UBS | — | Upgrade | Neutral → Buy | — | UBS: Neutral → Buy |
| 2024. 11. 20. | UBS | — | Upgrade | Sell → Neutral | — | UBS: Sell → Neutral |
| 2024. 09. 12. | Erste Group | — | Upgrade | Hold → Buy | — | Erste Group: Hold → Buy |
| 2024. 08. 12. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2024. 05. 31. | Argus Research | — | Maintain | Buy → Buy | — | Argus Research: Buy |
| 2024. 05. 30. | Goldman Sachs | — | Initiate coverage | — → Buy | — | Goldman Sachs: Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,233,965 | $243.36B | 0.44% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 2,180,476 | $200.45B | 0.31% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,852,741 | $170.32B | 0.28% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 203,026 | $40.04B | 0.03% | — | New position |